First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Amemiya T, Michiwaki Y, Fujioka Y, Takigawa K, Suzuki SO, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iihara K.
Hata N, et al. Among authors: fujioka y.
J Neurooncol. 2020 Feb;146(3):451-458. doi: 10.1007/s11060-019-03339-0. Epub 2020 Feb 4.
J Neurooncol. 2020.
PMID: 32020475